HOME >> MEDICINE >> NEWS
Artificial cervical disc replacement offered for neck and arm pain problems

(CHICAGO) Rush University Medical Center is one of the few sites in the country selected to participate in a clinical trial for the Artificial Cervical (neck) Disc, the latest technology in the field. The objective of the study is to evaluate the safety and effectiveness of the Porous Coated Motion (PCM) Artificial Disc for treatment of degenerative disc disease compared to conventional anterior cervical discectomy and spinal fusion surgery.

Cervical disc degeneration is a common cause of neck and arm pain that can greatly impact quality of life. The disc is a flexible material between the vertebrae that holds the bones together while still allowing for movement. Because of the demands put on the disc, it sometimes can 'herniate' or wear down causing pain. If treatments, such as rest, medications, physical therapy and activity modification are not successful, the standard surgical treatment is to remove the disc and then use a graft of bone and plate with screws to fuse the two vertebrae together.

According to Dr. Frank Phillips, orthopedic surgeon at Rush and primary investigator for the PCM Artificial Disc trial, spinal fusion is a highly successful operation for relieving symptoms, but there are potential drawbacks over time. The permanent fusion of bone eliminates natural movement between the vertebrae resulting in increased stress on the discs above and below the fusion. This additional pressure may cause excessive wear and tear on the adjacent discs, which may lead to more pain and the need for additional surgery.

"The goal is to find an implant that can simulate the natural function of the cervical disc and restore the physiologic motion of the cervical spine," said Phillips.

The PCM Artificial Cervical Disc combines the use of metal and plastic, the same materials that have been in use for 30 years in hip and knee replacements, to mimic the function of the disc. The implant has two halves: an upper metal (Cobalt Chrome a
'"/>

Contact: Kim Waterman
Kimberly_Waterman@rush.edu
312-942-7820
Rush University Medical Center
23-Sep-2005


Page: 1 2 3

Related medicine news :

1. Artificial light at night stimulates breast cancer growth in laboratory mice
2. Papillomavirus vaccine could substantially reduce cervical cancer incidence
3. Study shows continued success for new HPV vaccine against virus responsible for cervical cancer
4. Girls born with HIV infection at higher risk for cervical problems
5. Temple University Hospital investigates treatment for cervical dysplasia
6. NIH scientists honored for FDA-approved cervical cancer vaccine breakthrough
7. EU should make vaccination against cervical cancer virus mandatory for adolescent girls
8. HIV drug could be used to prevent cervical cancer, say University of Manchester researchers
9. New vaccine prevents cervical cancer in teens
10. New strategy more sensitive at detecting cervical cancer than smear test
11. Merck and GSK need to overcome cultural barriers to cervical cancer vaccine roll-out

Post Your Comments:
(Date:3/28/2015)... Rocket Pure , a manufacturer of natural body ... new natural sunscreen. They are offering the sunscreen in ... come with a bonus lip balm sunscreen. , The new ... Click to see the natural sunscreen on Amazon . ... made with non-nano zinc oxide and provides broad-based protection against ...
(Date:3/28/2015)... With more than 4,500 scientists, clinicians and ... and musculoskeletal diseases gathered here for the World ... time in the 17-year history of the field’s ... is an emerging non-pharmaceutical protocol for enhancing bone ... Wolff’s law, osteogenic loading at multiples of body ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 An article ... problem which could prove critical to organizations that deal ... a critical aspect of data security, is worsening . ... data security report, every major category out of the ... penetration testing. “With all the craziness that has gone ...
(Date:3/28/2015)... 28, 2015 Delaying rotator cuff surgery ... according to research presented today at the American Orthopaedic ... , “Our study compared results for 170 patients who ... additional glenohumeral joint capsule release procedure to relieve stiffness ... PhD, lead author from St. George Hospital in Sydney, ...
(Date:3/28/2015)... Omaha, NE (PRWEB) March 28, 2015 ... leader in healthcare staffing, including physical therapy jobs, ... exhibitor at the Ohio Physical Therapy Association Annual ... the Renaissance Columbus Downtown Hotel in Columbus, OH. ... programming, networking opportunities, and exhibits with products and ...
Breaking Medicine News(10 mins):Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 2Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 3Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2
(Date:3/27/2015)... , March 27, 2015   Hospira, Inc. ... in biosimilars and the world,s leading provider of ... that support an evaluation of biosimilarity of its ... and Drug Administration (FDA) conditionally approved name of ... (epoetin alfa). These study data were presented at ...
(Date:3/27/2015)... NEW YORK , March 27, 2015 /PRNewswire/ ... specialty pharmaceutical and medical device company focused on ... primary and metastatic liver cancers, announces the reporting ... the Company,s Melphalan Hydrochloride for Injection with the ... therapies in a poster presentation at the Society of ...
(Date:3/26/2015)... March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ... a focus on Omega-3 therapies for cardiovascular disease and ... issued 763,752 common shares of the Corporation (the "Common ... the period of December 5 th , 2014 to ... Notes that is due on or before April 1, ...
Breaking Medicine Technology:Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2
Cached News: